Eli Lilly has revised its revenue forecast for 2024 after seeing weaker-than-expected growth for its diabetes and obesity ...

JPM25 is in full swing as several pharma powerhouses—including Merck, Lilly and Amgen—detail their strategies for growth in ...

Eli Lilly (NYSE: LLY) saw its stock decline sharply by 6.5% on January 14, following the release of its fourth-quarter 2024 ...

World stocks were mixed on Wednesday following Wall Street’s mostly positive performance before key U.S. inflation data that ...

The results are an uncomfortable echo of late October 2024, when Mounjaro and Zepbound missed by similar margins. Those ...

Eli Lilly’s stock was set to suffer its worst day in four years after sales of diabetes and obesity drugs Mounjaro and Zepbound missed expectations.

Chris Schott, an analyst from J.P. Morgan, maintained the Buy rating on Eli Lilly & Co (LLY – Research Report). The associated price target ...

Compounding pharmacies must now cease producing their own versions of Zepbound/Mounjaro within a set time period. HealthDay ...

tirzepatide — the active ingredient in Zepbound and its counterpart Mounjaro for diabetes — is fully available again. "FDA has determined that the shortage of tirzepatide injection products ...

The United States Food and Drug Administration says the shortage of Eli Lilly’s Zepbound and Mounjaro drugs has been resolved and that specialty pharmacies and online companies need to stop ...

which led him to enlist the aid of the injectable medication Zepbound, which the Food and Drug Administration approved last year to treat obesity. Like Mounjaro, Zepbound is a brand name for ...